Effects of beta3 adrenergic receptor agonist on Myocardial Ischemia and Reperfusion

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K09417
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55060:Emergency medicine-related
• Research Institution: Okayama University
• Principal Investigator: Kuroko Yosuke 岡山大学, 大学病院, 講師 (20459184)
• Co-Investigator(Kenkyū-buntansha): 清水 秀二 国立研究開発法人国立循環器病研究センター, 研究所, 室長 (80443498) ; 笠原 真悟 岡山大学, 医歯薬学域, 教授 (90233692) ; 小谷 恭弘 岡山大学, 医歯薬学域, 准教授 (90534678)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 心臓マイクロダイアリシス / β３受容体作動薬 / 心筋虚血再還流障害

Outline of Final Research Achievements

Beta3 adrenergic receptor agonist has been documented to exert cardioprotective effects via endothelial NO synthase. We investigated these effects employing the cardiac microdialysis technique. We quantified dialysate myoglobin levels in anesthetized rats during myocardial ischemia and reperfusion. The dialysate myoglobin levels exhibited a slight increase during myocardial ischemia and a significant surge during myocardial reperfusion. Subsequently, we measured dialysate myoglobin levels with local administration of Mirabegron (a beta3 adrenergic receptor agonist) via a microdialysis probe. Due to societal issues (the coronavirus pandemic), data are not yet fully available. This study is ongoing.

Free Research Field

心臓血管外科

Academic Significance and Societal Importance of the Research Achievements

本研究において、β3アドレナリン受容体の役割や心筋保護効果のメカニズムを解き明かすことができれば、β3アドレナリン受容体を介した心筋虚血・再灌流障害に対する新たな薬物治療法の開発に繋がり、急性心筋梗塞患者の生命予後の改善や心筋梗塞後の心不全による再入院を減らすことが期待出来ると考えている。